[HTML][HTML] Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients
MD Stegall, T Diwan, S Raghavaiah, LD Cornell… - American journal of …, 2011 - Elsevier
Sensitized renal transplant recipients with high levels of donor-specific alloantibody (DSA)
commonly develop antibody-mediated rejection (AMR), which may cause acute graft loss or
shorten allograft survival. We examined the efficacy of terminal complement inhibition with
the humanized anti-C5 antibody, eculizumab, in the prevention AMR in renal transplant
recipients with a positive crossmatch against their living donor. The incidence of biopsy-
proven AMR in the first 3 months posttransplant in 26 highly sensitized recipients of living …
commonly develop antibody-mediated rejection (AMR), which may cause acute graft loss or
shorten allograft survival. We examined the efficacy of terminal complement inhibition with
the humanized anti-C5 antibody, eculizumab, in the prevention AMR in renal transplant
recipients with a positive crossmatch against their living donor. The incidence of biopsy-
proven AMR in the first 3 months posttransplant in 26 highly sensitized recipients of living …